Industry bigwigs are teaming up to create the first medical device industry association focused solely on Asia. The member companies of the just-launched Asia Pacific Medical Technology Association include Abbott, Baxter, B. Braun, Becton Dickinson, Boston Scientific, Cardinal Health, GE Healthcare, Johnson & Johnson, Medtronic, Philips, Siemens, Stryker and Zimmer.
As tensions begin to ease between the U.S. and Cuba, partnership opportunities may arise for stateside drugmakers--and Regeneron CEO Len Schleifer is heading down to the country to help get the ball rolling.
In December, Serum Institute of India reported victory in a Phase I trial of its powdered measles vaccine. But it may have to go back to the drawing board as results from a noninferiority trial reported Thursday showed that the powdered candidate was not as effective as the traditional injected vaccine.
India is planning to open its first medical device industrial park in Gujarat, the state whose strong economic performance propelled Narendra Modi, its former chief minister, to the prime ministership. Discussions are under way for a second park in the south Indian state of Tamil Nadu.
Sanofi says it is "flipping the model" in its launch of the first approved vaccine to treat dengue. It will submit it for approval in dengue-stricken nations rather than first filing regulatory submissions in the U.S. and Europe.
Some Western drugmakers have built plants in Indonesia to tap a market with a growing population and expanding national health coverage. But a new report suggests that the better entré for local production might be to buy a facility from a domestic producer.
California's Hansen Medical inked a distribution deal with a Chinese medical device company for its intravascular robotic system, a feather in Hansen's cap as it looks to expand commercialization for its device.
Dr. Reddy's Laboratories is looking to expand its market footprint, eyeing as much as $1 billion in potential deals and higher-end products like generic injectable drugs to chart growth and diversify its offerings.
U.K. contractor Ergomed has made Asian landfall, opening an office in Taiwan with eyes on forging traditional CRO deals and signing risk-sharing agreements with drugmakers.
After issuing an import alert last year for an IPCA Laboratories API plant in India where employees had been falsifying drug testing results and deleting failed tests, the FDA began looking at its operations further upstream and has now banned products from two of IPCA's finished product facilities.